| Assessment Status | Rapid Review Complete |
| HTA ID | 23033 |
| Drug | Beclometasone dipropionate anhydrous + formoterol fumarate dihydrate + glycopyrronium bromide |
| Brand | Trimbow® |
| Indication | Beclometasone dipropionate anhydrous + formoterol fumarate dihydrate + glycopyrronium bromide (Trimbow®) is indicated for maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disorder (COPD) who are not adequately treated by a combination of an inhaled corticosteroid (ICS) and a long-acting beta2-agonist (LABA) or a combination of a long-acting beta2-agonist (LABA) and a long-acting muscarinic antagonist (LAMA). |
| Assessment Process | |
| Rapid review commissioned | 21/06/2023 |
| Rapid review completed | 19/07/2023 |
| Rapid review outcome | A full HTA is not recommended. The NCPE recommends that Trimbow® for this indication not be considered for reimbursement at the submitted price*. |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
